盐酸安罗替尼治疗晚期非小细胞肺癌的临床探讨

Clinical Study of Anlotinib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer

目的探析晚期非小细胞肺癌患者应用盐酸安罗替尼治疗的临床效果。方法对该院2018年7月—2019年6月期间收治的68例晚期非小细胞肺癌患者进行回顾性分析,分组方法为随机数字表法,对照组32例,实验组36例。对照组采取支持对症治疗,实验组应用盐酸安罗替尼治疗,对比分析两组患者临床疗效、血清癌胚抗原(CEA)、生存质量评分及不良反应发生情况。结果针对临床疗效而言,实验组治疗客观有效率、疾病控制率分别为13.89%、69.44%明显高于对照组,差异有统计学意义(χ2=4.800、9.890,P<0.05);实验组治疗后CEA水平、生存质量评分分别为(12.08±2.12)ng/mL、(62.31±4.27)分,明显优于对照组,差异有统计学意义(t=6.130、7.120,P<0.05);实验组手足综合征、高血压、黏膜毒性发生率分别为13.89%、33.33%、13.89%,与对照组比较差异有统计学意义(χ2=4.800、10.000、4.800,P<0.05);实验组无进展生存期、总生存期分别为(5.27±0.61)、(7.46±1.21)个月,明显长于对照组,差异有统计学意义(t=10.320、10.120,P<0.05)。结论晚期非小细胞肺癌患者应用盐酸安罗替尼治疗的临床效果更加理想,有助于提高治疗效果,改善生存质量,值得临床应用与推广。

Objective To explore the clinical effect of anlotinib hydrochloride in patients with advanced non-small cell lung cancer.Methods A retrospective analysis was performed on 68 patients with advanced non-small cell lung cancer admitted to the hospital from July 2018 to June 2019.The grouping method was random number table method,with 32 cases in the control group and 36 cases in the experimental group.The control group was treated with supportive symptomatic treatment,and the experimental group was treated with anlotinib hydrochloride.The clinical efficacy,serum carcinoembryonic antigen(CEA),quality of life score and adverse reactions were compared and analyzed between the two groups.Results In terms of clinical efficacy,the objective treatment efficiency and disease control rate of the experimental group were 13.89%and 69.44%,respectively,which were significantly higher than those of the control group,the difference was statistically significant(χ2=4.800,9.890,P<0.05);after treatment,the CEA level and quality of life scores in the experimental group were(12.08±2.12)ng/mL and(62.31±4.27)points,which were significantly better than those in the control group,the difference was statistically significant(t=6.130,7.120,P<0.05);the incidence of hand-foot syndrome,hypertension,and mucosal toxicity in the experimental group were 13.89%,33.33%,and 13.89%,respectively,which were significantly different from those in the control group,the difference was statistically significant(χ2=4.800,10.000,4.800,P<0.05);the progression-free survival and overall survival of the experimental group were(5.27±0.61)months and(7.46±1.21)months,respectively,which were significantly longer than those of the control group,the difference was statistically significant(t=10.320,10.120,P<0.05).Conclusion The clinical effect of anlotinib hydrochloride treatment in patients with advanced non-small cell lung cancer is more ideal,which is helpful to improve the treatment effect and improve the quality of life.It is worthy of clinical application and promotion.